Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications studying cancer adverse outcome nononcological therapies review food drug
… models (cost effectiveness, budget impact) Drug utilization studies Economic burden of illness studies …
… in an operating room (OR). In November, the U.S. Food and Drug Administration (FDA) granted approval to Tusker …
Navigating EU Joint Clinical Assessments and Joint Scientific Consultations From January 2025 Onward
… which applies to all new oncology drugs and cell and gene therapies from January 2025, orphan medicinal products from …
… She did her postdoctoral training at the Center for Drug Evaluation and Research in the United States Food and Drug Administration. Dr. Margulis has conducted … case-control and cohort studies; methods research; and outcome and covariate validation, as well as in developing …
… States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new … K. Transcript The Institute for Clinical and Economic Review, or ICER, is an independent organization that … comparative net health benefit. We conducted a systematic review of evidence reports to better understand how evidence …
… by the Swedish National Committee for Nutrition and Food Sciences and the Swedish Food Agency. Presentation Details: 14 November, 1:40pm The …
… Our team has negotiated with the FDA’s Clinical Outcome Assessments (COA) team and a wide variety of …
… models (cost effectiveness, budget impact) Drug utilization studies Epidemiology of disease Exploratory …
Collaborative Regulatory RWE Research Through our Barcelona based team, we are a partner center of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) which is led by the European Medicines Agency. We are dedicated to …
… Collecting, analyzing, and interpreting patient-reported outcome (PRO) data for oncology trials can present unique … The specific challenges associated with data analysis from cancer studies. Why safety and patient-reported outcome endpoints may appear contradictory in cancer trials. Why traditional statistical methods for …